Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Berger JR, et al. Among authors: centonze d. Ann Neurol. 2010 Sep;68(3):409-11. doi: 10.1002/ana.22083. Ann Neurol. 2010. PMID: 20818795 No abstract available.
Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis.
Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, Musella A, Bergami A, Muzio L, Bernardi G, Battistini L, Martino G, Centonze D. Rossi S, et al. Among authors: centonze d. Ann Neurol. 2012 Jan;71(1):76-83. doi: 10.1002/ana.22512. Ann Neurol. 2012. PMID: 22275254
CD19 as a molecular target in CNS autoimmunity.
Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V. Stüve O, et al. Among authors: centonze d. Acta Neuropathol. 2014 Aug;128(2):177-90. doi: 10.1007/s00401-014-1313-z. Epub 2014 Jul 4. Acta Neuropathol. 2014. PMID: 24993505 Free PMC article. Review.
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C. Prosperini L, et al. Among authors: centonze d. J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22. J Neurol. 2017. PMID: 27878443
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group. Comi G, et al. Among authors: centonze d. J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23. J Neurol. 2017. PMID: 29063244 Free PMC article. Clinical Trial.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
616 results